MVC's ENVACGEN® is Granted First Enterovirus A71 Vaccine Marketing Authorization in Vietnam; Joins Forces with Substipharm Biologics to Expand Southeast Asian Market
TAIPEI and GENEVA, March 18, 2026 /PRNewswire/ -- Medigen Vaccine Biologics Corp. (MVC) and Substipharm Biologics announced on March 17 that ENVACGEN®, an Enterovirus 71 (EV-A71) vaccine, has received marketing authorization from the Drug...
Medigen Vaccine Biologics Corp Collaborates with Substipharm Biologics Expanding ENVACGEN® Enterovirus A71 Vaccine Market in Southeast Asia
TAIPEI and GENEVA, Jan. 9, 2025 /PRNewswire/ -- Medigen Vaccine Biologics Corp (MVC) has signed a regional distribution agreement with the pharmaceutical company Substipharm Biologics to expand the market reach of enterovirus vaccine products in...